A detailed history of China Universal Asset Management Co., Ltd. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 36,309 shares of ABUS stock, worth $115,825. This represents 0.02% of its overall portfolio holdings.

Number of Shares
36,309
Previous 22,171 63.77%
Holding current value
$115,825
Previous $68,000 104.41%
% of portfolio
0.02%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$3.12 - $4.56 $44,110 - $64,469
14,138 Added 63.77%
36,309 $139,000
Q2 2024

Jul 19, 2024

SELL
$2.52 - $3.63 $25,356 - $36,525
-10,062 Reduced 31.22%
22,171 $68,000
Q1 2024

Apr 29, 2024

BUY
$2.26 - $2.92 $29,002 - $37,472
12,833 Added 66.15%
32,233 $83,000
Q4 2023

May 21, 2024

SELL
$1.69 - $2.54 $21,687 - $32,595
-12,833 Reduced 39.81%
19,400 $48,000
Q4 2023

Jan 23, 2024

BUY
$1.69 - $2.54 $25,525 - $38,364
15,104 Added 351.58%
19,400 $49,000
Q3 2023

May 21, 2024

BUY
$1.9 - $2.27 $4,026 - $4,810
2,119 Added 97.34%
4,296 $8,000
Q3 2023

Oct 30, 2023

BUY
$1.9 - $2.27 $4,026 - $4,810
2,119 Added 97.34%
4,296 $9,000
Q2 2023

May 21, 2024

BUY
$2.24 - $3.06 $127 - $174
57 Added 2.69%
2,177 $5,000
Q2 2023

Jul 27, 2023

BUY
$2.24 - $3.06 $127 - $174
57 Added 2.69%
2,177 $5,000
Q1 2023

May 21, 2024

BUY
$2.23 - $3.1 $1,181 - $1,643
530 Added 33.33%
2,120 $6,000
Q1 2023

Apr 27, 2023

BUY
$2.23 - $3.1 $1,181 - $1,643
530 Added 33.33%
2,120 $6,000
Q4 2022

May 21, 2024

SELL
$1.91 - $2.85 $58,528 - $87,332
-30,643 Reduced 95.07%
1,590 $3,000
Q4 2022

Jan 31, 2023

BUY
$1.91 - $2.85 $355 - $530
186 Added 13.25%
1,590 $4,000
Q3 2022

Oct 21, 2022

BUY
$1.88 - $2.88 $2,639 - $4,043
1,404 New
1,404 $3,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $478M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.